Pulmonary emphysema is a chronic, progressive lung disease characterized by the irreversible destruction of alveoli, the tiny air sacs in the lungs responsible for gas exchange, leading to impaired respiratory function and reduced oxygenation of the blood [1]. It is one of the primary forms of chronic obstructive pulmonary disease (COPD), alongside chronic bronchitis, and is most commonly caused by long-term exposure to cigarette smoke, which triggers chronic inflammation and protease-antiprotease imbalance in the lungs [2]. The hallmark of emphysema is the loss of pulmonary elasticity and alveolar wall destruction, resulting in air trapping, hyperinflation, and progressive shortness of breath (dyspnea), especially during physical exertion [3]. A key pathophysiological mechanism involves the imbalance between proteases such as neutrophil elastase and antiproteases like alpha-1 antitrypsin, particularly evident in individuals with genetic deficiency of this protective protein [4]. Diagnosis typically relies on pulmonary function tests, where a post-bronchodilator FEV1/FVC ratio < 0.7 confirms airflow obstruction, supported by imaging such as high-resolution CT scans that reveal areas of low attenuation indicative of alveolar destruction [5]. Management focuses on smoking cessation—the most effective intervention to slow disease progression—alongside pharmacological treatments including long-acting bronchodilators, inhaled corticosteroids, and in severe cases, oxygen therapy or surgical interventions such as lung volume reduction surgery [6]. The disease also contributes to systemic complications including pulmonary hypertension and cor pulmonale, underscoring its impact beyond the lungs [7]. Public health efforts in countries like Brazil have significantly reduced smoking rates through policies aligned with the WHO’s MPOWER framework, although recent increases in smoking prevalence threaten to reverse these gains [8]. Early detection via spirometric screening in at-risk populations and comprehensive pulmonary rehabilitation programs are critical to improving outcomes and reducing the substantial economic burden of COPD on healthcare systems such as the Brazilian public health system (SUS) [9].

Pathophysiology and Mechanisms of Lung Damage

Pulmonary emphysema is characterized by a complex and progressive disruption of lung architecture, primarily driven by the irreversible destruction of alveolar walls and a profound loss of pulmonary elasticity. This structural damage leads to air trapping, hyperinflation, and impaired gas exchange, forming the core of the disease's pathophysiology. The central mechanisms involve a critical imbalance between destructive proteolytic enzymes and their protective inhibitors, sustained by chronic inflammation, oxidative stress, and cellular senescence.

Protease-Antiprotease Imbalance: The Core Mechanism

The fundamental pathophysiological mechanism of emphysema is the protease-antiprotease imbalance, a concept most clearly exemplified by alpha-1 antitrypsin deficiency (AATD). In healthy lungs, proteolytic enzymes such as neutrophil elastase, released by inflammatory cells like neutrophils and macrophages, are kept in check by antiproteases, primarily alpha-1 antitrypsin (AAT). AAT is a serine protease inhibitor produced in the liver that effectively neutralizes elastase, preventing it from degrading essential structural proteins like elastin and collagen in the alveolar septa [10].

In emphysema, this balance is disrupted. Chronic exposure to irritants, most notably cigarette smoke, triggers a persistent inflammatory response that recruits and activates neutrophils and macrophages. These cells release large quantities of proteases, including elastase, collagenases, and matrix metalloproteinases (MMPs). Simultaneously, cigarette smoke and other environmental factors generate oxidative stress, which can inactivate AAT by oxidizing a critical methionine residue, rendering it ineffective [11]. This double hit—increased protease activity and decreased antiprotease function—leads to the uncontrolled degradation of the extracellular matrix, particularly elastin, which is vital for the lung's elastic recoil. The resulting destruction of alveolar walls forms larger, less efficient air spaces, drastically reducing the surface area available for gas exchange [12].

Chronic Inflammation and Cellular Mediators

Chronic inflammation is the engine that drives the protease-antiprotease imbalance and tissue destruction. The activation of alveolar macrophages by inhaled particles, such as those in cigarette smoke, initiates the inflammatory cascade. These macrophages release a network of pro-inflammatory cytokines and chemokines that amplify and perpetuate the response. Key mediators include:

  • Tumor Necrosis Factor-alpha (TNF-α): A primary cytokine produced by macrophages that stimulates the production of other inflammatory molecules and activates the NF-κB signaling pathway, a master regulator of inflammation [13].
  • Interleukin-8 (IL-8/CXCL8): A potent chemokine that is crucial for the recruitment of neutrophils from the bloodstream into the lung tissue. Its expression is upregulated by TNF-α and cigarette smoke, creating a positive feedback loop that sustains neutrophilic inflammation [14].
  • CCL2 (MCP-1): This chemokine is essential for recruiting monocytes, which differentiate into macrophages in the lung, thereby maintaining the pool of inflammatory cells.
  • Interleukin-1β (IL-1β) and Interleukin-6 (IL-6): These cytokines further amplify the inflammatory response, promoting fever, acute-phase protein production, and additional leukocyte recruitment [15].

The persistent presence of these mediators creates a self-sustaining cycle of inflammation, leading to continuous protease release and progressive alveolar destruction.

Oxidative Stress and Its Consequences

Oxidative stress is a major contributor to emphysema pathogenesis, acting as a bridge between environmental exposures and cellular damage. Cigarette smoke contains thousands of oxidants that directly overwhelm the lung's antioxidant defenses, such as superoxide dismutase (SOD) and glutathione. This imbalance leads to the accumulation of reactive oxygen species (ROS), which cause direct damage to cellular components, including lipids (via lipid peroxidation), proteins, and DNA [16].

Beyond direct injury, oxidative stress amplifies inflammation by activating the NF-κB pathway, which increases the transcription of pro-inflammatory genes. It also inactivates AAT, as mentioned, and can induce apoptosis (programmed cell death) in lung cells. The compromised function of the Nrf2 pathway, a key cellular defense system that regulates the expression of antioxidant enzymes like heme oxygenase-1 (HO-1), is a critical factor. In smokers and emphysema patients, Nrf2 activity is often impaired, leaving the lung more vulnerable to oxidative damage [17].

Cellular Senescence and Failed Repair

Another critical mechanism in emphysema is cellular senescence, a state of irreversible cell cycle arrest. Chronic inflammation and oxidative stress induce senescence in key lung cells, including alveolar epithelial cells, endothelial cells, and fibroblasts. While senescence is a protective mechanism against cancer, the accumulation of senescent cells in the lung has detrimental effects.

Senescent cells develop a senescence-associated secretory phenotype (SASP), where they secrete a cocktail of pro-inflammatory cytokines, chemokines, and proteases (like MMP-9 and MMP-12). This SASP perpetuates local inflammation, recruits more immune cells, and directly contributes to the degradation of the extracellular matrix [10]. Furthermore, senescent cells lose their ability to proliferate and repair damaged tissue. This failure of regenerative capacity means that the lung cannot effectively restore its architecture after injury, leading to the progressive, irreversible loss of alveolar structure that defines emphysema [19].

Mechanical Consequences: Loss of Elastic Recoil and Airflow Obstruction

The combined effects of alveolar destruction and elastin degradation result in a catastrophic loss of elastic recoil. In a healthy lung, elastic recoil is the primary force that drives air out during expiration. In emphysema, the loss of this elastic force means the lungs cannot contract effectively, leading to air trapping and pulmonary hyperinflation. This is reflected clinically by an increased residual volume (RV) and total lung capacity (TLC) [20].

This mechanical failure also leads to expiratory airflow obstruction through a phenomenon known as dynamic airway collapse. The small airways (bronchioles) are normally held open by radial traction from the surrounding alveolar tissue. As the alveolar walls are destroyed, this supportive traction is lost. During forced expiration, when intrathoracic pressure increases, the unsupported bronchioles collapse prematurely, creating a physical obstruction to airflow. This is distinct from the bronchospasm seen in asthma and is a direct consequence of the structural damage to the lung parenchyma [21].

Causes and Risk Factors

Pulmonary emphysema is a complex disease resulting from the interplay of environmental exposures, genetic predispositions, and chronic inflammatory processes. The primary cause is long-term exposure to noxious particles and gases, particularly cigarette smoke, which initiates a cascade of pathological events leading to irreversible alveolar destruction. However, other environmental and genetic factors also significantly contribute to disease development, especially in non-smokers or individuals with heightened susceptibility.

Cigarette Smoking: The Primary Environmental Risk Factor

Cigarette smoking is the leading cause of pulmonary emphysema, accounting for approximately 80% to 90% of cases [22]. The inhalation of tobacco smoke triggers a persistent inflammatory response in the lungs, characterized by the recruitment of immune cells such as neutrophils and macrophages. These cells release proteolytic enzymes, including neutrophil elastase and matrix metalloproteinases (MMPs), which degrade the structural proteins of the alveolar walls, particularly elastin and collagen [2]. This enzymatic destruction leads to the formation of abnormally large air spaces, loss of pulmonary elasticity, and impaired gas exchange. The chronic nature of this inflammation, driven by continued smoking, results in progressive and irreversible damage to the lung parenchyma. In high-income countries, tobacco is responsible for more than 70% of emphysema cases [24].

Environmental and Occupational Exposures

Beyond tobacco, exposure to various environmental and occupational pollutants significantly increases the risk of developing emphysema. This includes ambient air pollution, urban traffic emissions, industrial fumes, and chemical vapors. In developing countries, a major contributor is the exposure to smoke from biomass fuels, such as wood or charcoal, used for cooking and heating in poorly ventilated homes [25]. This form of indoor air pollution is a significant cause of obstructive lung diseases, including emphysema, in these regions [26]. Occupational exposures in industries such as mining, construction, and manufacturing, where workers are exposed to dusts and toxic gases, can also lead to lung damage and emphysema, with studies suggesting that up to 20% of COPD cases may be attributable to occupational hazards [27]. These exposures act synergistically with other risk factors, such as smoking, to accelerate lung function decline.

Genetic Predisposition: Alpha-1 Antitrypsin Deficiency

A key genetic risk factor for emphysema is alpha-1 antitrypsin deficiency (AATD), an autosomal recessive disorder caused by mutations in the SERPINA1 gene [4]. Alpha-1 antitrypsin (AAT) is a major antiprotease produced in the liver that inhibits neutrophil elastase, protecting the lung's elastic fibers from degradation. Individuals with severe deficiency, particularly those with the ZZ phenotype, have very low levels of functional AAT, leading to an unchecked protease-antiprotease imbalance. This results in premature and severe destruction of the alveolar walls, often leading to emphysema in the lower lobes of the lungs, even in the absence of a smoking history [29]. Patients with AATD are typically diagnosed at a younger age, often before 40, highlighting the powerful role of this genetic factor in disease pathogenesis [24]. The condition exemplifies the critical role of the protease-antiprotease equilibrium in maintaining lung integrity.

Other Contributing Risk Factors

Several other factors can increase an individual's susceptibility to emphysema. A history of respiratory diseases in childhood, such as recurrent infections or poorly controlled asthma, may impair lung development and increase vulnerability to later damage [24]. Exposure to secondhand smoke is another significant risk factor, contributing to lung inflammation and damage in non-smokers. Furthermore, the interaction between environmental exposures and genetic factors can be profound; for example, oxidative stress from cigarette smoke can inactivate AAT even in individuals with normal genotypes, exacerbating the protease-antiprotease imbalance [11]. This complex interplay of factors underscores that while smoking is the predominant cause, emphysema can also occur in non-smokers due to a combination of genetic and environmental influences [33]. The convergence of these risk factors on a common pathway of chronic inflammation and proteolytic tissue destruction is central to the disease's pathogenesis [34].

Clinical Symptoms and Disease Progression

Pulmonary emphysema is a chronic and progressive disease characterized by the irreversible destruction of alveoli, leading to impaired gas exchange and respiratory function. The clinical presentation evolves gradually, with symptoms becoming increasingly severe over time, significantly impacting patients' quality of life. The hallmark symptom is progressive dyspnea, which initially occurs during exertion but may eventually manifest even at rest in advanced stages [35]. This breathlessness results from the loss of pulmonary elasticity and alveolar wall destruction, which impairs the lungs’ ability to expel air effectively, leading to air trapping and hyperinflation.

Early and Common Symptoms

In the early stages, symptoms of pulmonary emphysema are often subtle and may be overlooked. The most common initial symptom is exertional dyspnea, such as shortness of breath while climbing stairs or walking quickly. This is frequently accompanied by a persistent, dry or minimally productive cough [36]. Patients may also experience wheezing (sibilance) and a sensation of chest tightness due to the difficulty in fully expiring air. Rapid breathing and fatigue are common, as the body exerts increased effort to maintain adequate oxygenation [3].

The clinical phenotype often associated with emphysema is known as the “pink puffer,” in contrast to the “blue bloater” phenotype of chronic bronchitis. Pink puffers are typically thin, use accessory respiratory muscles, breathe rapidly and shallowly, and maintain relatively normal oxygen levels due to compensatory hyperventilation, hence their pink complexion [38]. This phenotype reflects the predominance of alveolar destruction and airway collapse over mucus hypersecretion.

Disease Progression and Advanced Symptoms

As the disease progresses, symptoms intensify and begin to interfere with daily activities. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system, the severity of airflow limitation—measured by post-bronchodilator FEV1 (forced expiratory volume in one second)—correlates with clinical deterioration [39]. In moderate stages (FEV1 50–79% of predicted), dyspnea becomes evident during routine tasks. In severe (FEV1 30–49%) and very severe (FEV1 <30%) stages, patients experience constant breathlessness, even at rest.

Advanced emphysema is associated with significant systemic effects. Unintentional weight loss and muscle wasting occur due to the high energy cost of breathing and chronic inflammation [36]. Cyanosis—bluish discoloration of the lips and fingertips—may develop, indicating hypoxemia, or low blood oxygen levels [41]. Peripheral edema, particularly in the ankles and legs, is a sign of cor pulmonale, a form of right-sided heart failure caused by pulmonary hypertension resulting from chronic lung disease [7]. Patients also become more susceptible to recurrent respiratory infections such as bronchitis and pneumonia, which can trigger acute exacerbations and accelerate functional decline [43].

Factors Influencing Disease Progression

The rate of disease progression varies among individuals and is influenced by several key factors. Continued smoking is the most significant accelerator of lung function decline, with smokers experiencing a faster rate of FEV1 reduction compared to ex-smokers [41]. Environmental exposures, such as air pollution, occupational dusts, and chemical vapors, also contribute to worsening lung damage [26]. Genetic predisposition, particularly alpha-1 antitrypsin deficiency (AATD), leads to earlier onset and more rapid progression of emphysema, often diagnosed before age 40 even in non-smokers [29].

Prognosis and Clinical Management

Although emphysema is irreversible, its progression can be significantly slowed through effective interventions. Smoking cessation remains the single most effective measure to reduce the rate of lung function decline and improve long-term survival [41]. Pharmacological treatments such as long-acting bronchodilators and inhaled corticosteroids help manage symptoms and reduce exacerbations. Pulmonary rehabilitation programs, which include supervised exercise, nutritional counseling, and education, enhance functional capacity and quality of life [48].

In advanced cases, long-term oxygen therapy is indicated for patients with chronic hypoxemia (PaO₂ ≤ 55 mm Hg), significantly improving survival [49]. For select patients with heterogeneous emphysema, interventions such as lung volume reduction surgery or endobronchial valves may be considered to improve lung mechanics and exercise tolerance [50].

Early detection through spirometric screening in at-risk populations—especially smokers over 40 years of age—is critical for timely intervention and preservation of lung function [51]. By integrating clinical assessment, functional testing, and imaging, healthcare providers can better stratify risk, monitor progression, and tailor treatment strategies to individual patient needs.

Diagnostic Methods and Evaluation

The diagnosis of pulmonary emphysema involves a comprehensive assessment combining clinical evaluation, pulmonary function testing, and imaging studies to confirm the presence of irreversible airflow obstruction, characterize the extent of parenchymal destruction, and determine disease severity. Accurate diagnosis is essential for appropriate classification, treatment planning, and monitoring of disease progression. The primary diagnostic tools include spirometry, high-resolution computed tomography (CT), arterial blood gas (ABG) analysis, and additional functional and laboratory tests that support the clinical picture.

Pulmonary Function Testing: Spirometry and Beyond

Spirometry is the cornerstone of diagnosing pulmonary emphysema and is considered the most important and widely used test for confirming airflow obstruction [52]. This non-invasive, rapid test measures the volume and speed of air a patient can inhale and exhale. The key diagnostic criterion for emphysema, as part of chronic obstructive pulmonary disease (COPD), is a post-bronchodilator ratio of forced expiratory volume in one second (FEV₁) to forced vital capacity (FVC) of less than 0.70, indicating persistent airflow limitation [53]. This ratio is fundamental in distinguishing obstructive lung diseases like emphysema from restrictive patterns.

Beyond the FEV₁/FVC ratio, the absolute value of post-bronchodilator FEV₁ is used to classify disease severity according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines, ranging from mild (GOLD 1) to very severe (GOLD 4) [54]. In emphysema, spirometry often reveals additional abnormalities such as increased residual volume (RV) and total lung capacity (TLC), reflecting pulmonary hyperinflation due to loss of elastic recoil and air trapping [20]. These volumetric changes correlate directly with dyspnea and functional limitation.

Other specialized pulmonary function tests may be performed in specialized laboratories to further characterize the disease. These include lung volume measurements and diffusing capacity for carbon monoxide (DLCO), which is typically reduced in emphysema due to the destruction of alveolar surface area and capillary beds essential for gas exchange [56]. A markedly reduced DLCO is a functional marker suggestive of predominant emphysema, helping to differentiate it from other COPD phenotypes such as chronic bronchitis.

Imaging Studies: Chest Radiography and High-Resolution CT

Imaging plays a critical role in visualizing structural lung changes and confirming the diagnosis of emphysema. While chest radiography is often the initial imaging modality, it has limited sensitivity, particularly in early-stage disease [57]. However, it can reveal indirect signs of emphysema, including pulmonary hyperinflation, flattened diaphragms, an increased retrosternal space, and reduced vascular markings, especially in the upper lobes [58].

High-resolution computed tomography (HRCT) of the chest is the most sensitive and specific imaging technique for detecting, quantifying, and characterizing pulmonary emphysema [59]. HRCT allows direct visualization of alveolar wall destruction and the formation of abnormal air spaces. Key findings include areas of low attenuation (typically below -950 Hounsfield units), incomplete or absent septa, and bullae or areas of coalesced air spaces [5]. HRCT also enables the identification of emphysema distribution patterns—such as centrilobular (common in smokers, upper lobe predominant), panlobular (associated with alpha-1 antitrypsin deficiency, often diffuse or basal), and paraseptal—which can guide further evaluation and management [61].

Quantification of emphysema on HRCT is possible through the calculation of the low-attenuation volume (LAV%), which correlates strongly with functional impairment, hyperinflation, and clinical severity [62]. This quantitative approach is particularly valuable for phenotyping COPD, monitoring disease progression, and selecting candidates for interventions such as lung volume reduction surgery or endobronchial valve placement.

Arterial Blood Gas Analysis and Additional Laboratory Tests

Arterial blood gas (ABG) analysis is used to assess gas exchange efficiency and acid-base balance in patients with advanced emphysema. In severe disease, ABG typically reveals hypoxemia (reduced arterial oxygen pressure, PaO₂) and, in more advanced cases, hypercapnia (elevated arterial carbon dioxide pressure, PaCO₂), indicating respiratory failure [63]. This test is crucial for determining the need for long-term oxygen therapy, especially in patients with resting hypoxemia (PaO₂ ≤ 55 mmHg or saturation ≤ 88%) [64].

Additional laboratory tests may be employed to identify underlying causes or contributing factors. Blood tests to measure serum alpha-1 antitrypsin levels are recommended, particularly in younger patients, non-smokers, or those with basilar-predominant emphysema, to detect genetic deficiency that predisposes to early-onset emphysema [65]. If levels are low, further phenotyping and genotyping are performed to confirm the diagnosis. Other emerging biomarkers under investigation include desmosine (a marker of elastin degradation), inflammatory markers like C-reactive protein (CRP), interleukin-6 (IL-6), and markers of oxidative stress such as malondialdehyde (MDA), which reflect ongoing parenchymal destruction and inflammation [66].

Integration of Diagnostic Findings and Phenotyping

The combination of spirometry and imaging allows for the identification of distinct clinical phenotypes of COPD. For example, patients with predominant emphysema often present with the "pink puffer" phenotype—characterized by severe dyspnea, minimal cough, weight loss, and relatively preserved oxygenation due to compensatory hyperventilation—contrasted with the "blue bloater" phenotype of chronic bronchitis, marked by cyanosis, obesity, and frequent respiratory infections [1]. Recognizing these phenotypes has therapeutic implications, guiding decisions on oxygen therapy, pulmonary rehabilitation, and surgical or interventional options.

In summary, the diagnosis and evaluation of pulmonary emphysema rely on an integrated approach using spirometry to confirm airflow obstruction, HRCT to visualize and quantify parenchymal destruction, ABG to assess gas exchange, and targeted laboratory tests to identify genetic or systemic contributors. This multimodal assessment enables accurate staging, phenotyping, and personalized management, ultimately improving patient outcomes and reducing the long-term burden on healthcare systems such as the Brazilian public health system (SUS) [9].

Treatment and Disease Management

The management of pulmonary emphysema focuses on slowing disease progression, alleviating symptoms, improving quality of life, and preventing complications. As a chronic and irreversible condition, treatment requires a multidisciplinary approach that integrates pharmacological therapy, lifestyle modifications, non-pharmacological interventions, and, in select cases, surgical options. The cornerstone of effective disease management is early diagnosis and patient adherence to a comprehensive therapeutic plan.

Pharmacological Treatment

Medications play a central role in controlling symptoms and reducing the frequency of exacerbations in patients with pulmonary emphysema. The primary classes of drugs used include:

  • Bronchodilators: These are the most commonly prescribed medications and work by relaxing the smooth muscles of the airways, improving airflow and reducing breathlessness. They are available in short-acting (used as needed) and long-acting formulations (used daily). Long-acting muscarinic antagonists (LAMAs) such as tiotrópio and long-acting beta-agonists (LABAs) like formoterol are particularly effective in reducing hyperinflation and improving exercise tolerance [69]. The combination of LABA and LAMA has shown superior outcomes in symptom control and exacerbation reduction compared to monotherapy chronic obstructive pulmonary disease (COPD).

  • Inhaled corticosteroids (ICS): These are recommended for patients with frequent exacerbations or elevated inflammatory markers. ICS help reduce airway inflammation and are often combined with bronchodilators in fixed-dose inhalers such as Trelegy Ellipta (fluticasone, umeclidinium, vilanterol) [70]. However, long-term use must be balanced against potential side effects such as oral candidiasis and increased risk of pneumonia.

  • Phosphodiesterase-4 inhibitors: Roflumilast (Daxas) is indicated for severe COPD with chronic bronchitis and a history of exacerbations. It reduces inflammation by increasing cyclic AMP levels in immune cells and has been shown to decrease the rate of disease flare-ups [71].

Treatment selection follows guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), which recommend individualized therapy based on symptom severity, lung function, and exacerbation history [6].

Smoking Cessation and Behavioral Support

Smoking cessation is the single most effective intervention to slow the progression of pulmonary emphysema. Continued tobacco use accelerates the decline in lung function, particularly the forced expiratory volume in one second (FEV1), while quitting can stabilize this decline to near-normal aging rates [73]. Support strategies include behavioral counseling, nicotine replacement therapy (patches, gum), and pharmacological agents such as varenicline and bupropion, which significantly increase abstinence rates [74]. The Brazilian public health system (SUS) offers free cessation programs, including multidisciplinary follow-up, which have demonstrated success rates of up to 70% in some regions [75].

Pulmonary Rehabilitation

Pulmonary rehabilitation is a structured, evidence-based program that combines supervised exercise training, nutritional counseling, education about disease management, and psychological support. It is strongly recommended for patients with moderate to severe emphysema who experience persistent dyspnea despite pharmacological treatment [76]. Programs typically last 6 to 12 weeks and result in significant improvements in exercise capacity, as measured by the six-minute walk test (6MWT), reduced breathlessness (assessed by the mMRC scale), and enhanced quality of life (evaluated using tools like the St. George’s Respiratory Questionnaire) [77]. Home-based rehabilitation models have also proven effective, offering greater accessibility and cost-efficiency [78]. Rehabilitation is particularly beneficial in patients with the "pink puffer" phenotype, characterized by predominant emphysema and marked exertional dyspnea [1].

Long-Term Oxygen Therapy

Long-term oxygen therapy (LTOT) is indicated for patients with advanced emphysema and chronic hypoxemia. Criteria for initiation include an arterial oxygen pressure (PaO₂) ≤ 55 mmHg or oxygen saturation (SaO₂) ≤ 88% at rest, or PaO₂ between 56–59 mmHg with evidence of complications such as polycythemia, pulmonary hypertension, or cor pulmonale [80]. LTOT should be administered for at least 15 hours per day, preferably continuously, to achieve maximal benefit. The landmark NOTT and MRC trials demonstrated that continuous oxygen use reduces mortality by up to 50% in appropriately selected patients [81]. Additional benefits include improved cognitive function, reduced hospitalizations, and better hemodynamic stability by lowering pulmonary artery pressure [82].

Surgical and Interventional Therapies

For carefully selected patients with severe emphysema, surgical or minimally invasive interventions may be considered:

  • Lung volume reduction surgery (LVRS): This procedure involves removing hyperinflated, poorly functioning lung tissue, typically from the upper lobes, allowing the remaining healthier lung to expand and function more efficiently. It is most effective in patients with heterogeneous emphysema and good exercise capacity [83].

  • Endobronchial valves: These are one-way devices placed bronchoscopically in the airways leading to diseased lung regions. They promote atelectasis of the targeted lobe, reducing overall lung volume and improving mechanics. This option is suitable for patients with complete interlobar fissures and minimal collateral ventilation [76].

  • Lung transplantation: Reserved for patients with very severe disease (GOLD stage 4), good overall health, and no major comorbidities, lung transplantation can significantly improve quality of life and survival, although it carries significant risks including rejection and infection [50].

Management of Alpha-1 Antitrypsin Deficiency

In the rare subset of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD), specific therapy is available. Augmentation therapy involves weekly intravenous infusions of purified AAT protein, which helps restore protective levels in the lungs and slow the progression of alveolar destruction [86]. This treatment is most effective when initiated early and combined with smoking cessation and standard COPD management strategies.

Disease Monitoring and Preventive Measures

Effective long-term management includes regular follow-up with a pulmonologist, monitoring of lung function via spirometry, and vaccination against influenza and pneumococcal pneumonia to prevent respiratory infections. Patients should also avoid environmental irritants such as air pollution, occupational dusts, and chemical fumes. Nutritional support is crucial, as unintentional weight loss and muscle wasting are common in advanced disease and contribute to poor outcomes.

The integration of these strategies—pharmacological treatment, smoking cessation, rehabilitation, oxygen therapy, and, when appropriate, surgical options—forms the foundation of comprehensive disease management. By addressing both the physiological and psychosocial aspects of emphysema, this multifaceted approach aims to optimize patient outcomes and reduce the substantial burden of disease on healthcare systems such as the Brazilian public health system (SUS) [9].

Role of Smoking Cessation and Public Health Policies

Smoking cessation is the single most effective intervention for altering the natural course of pulmonary emphysema, a progressive and irreversible form of chronic obstructive pulmonary disease (COPD) [74]. While it cannot reverse established structural damage to the alveoli, quitting smoking significantly slows the accelerated decline in lung function, particularly the loss of forced expiratory volume in one second (FEV1), and reduces the frequency of acute exacerbations, hospitalizations, and systemic complications such as lung cancer and cardiovascular disease [73]. Scientific evidence demonstrates that upon cessation, the rate of FEV1 decline in former smokers approaches that of individuals who have never smoked, thereby stabilizing the disease and improving long-term prognosis [74]. Even after a diagnosis of emphysema, cessation leads to a partial recovery of respiratory function, including improved mucociliary clearance, reduced airway inflammation, and decreased mucus production, resulting in symptomatic relief such as reduced chronic cough and dyspnea [91]. The earlier the cessation occurs, the greater the benefit in terms of preserved lung function and increased life expectancy [92].

Public Health Policies and the MPOWER Framework

Public health policies have been instrumental in reducing smoking prevalence and, consequently, the burden of emphysema. Brazil is a global leader in tobacco control, having implemented a comprehensive set of policies aligned with the World Health Organization's MPOWER framework [93]. This strategy includes monitoring tobacco use, protecting people from tobacco smoke, offering help to quit, warning about the dangers of tobacco, enforcing bans on advertising, promotion, and sponsorship, and raising taxes on tobacco products [93]. These measures have led to a dramatic decline in adult smoking rates in Brazil, from 15.7% in 2008 to 9.1% in 2023, one of the most significant reductions worldwide [93]. The policy of increasing taxes on cigarettes is considered one of the most effective tools for reducing consumption, particularly among youth and low-income populations [96]. However, a concerning reversal occurred in 2024, with the smoking rate increasing to 11.6%, highlighting the need for sustained and strengthened efforts to prevent a resurgence of tobacco-related diseases like emphysema [97].

Education, Cessation Programs, and Health System Integration

Effective strategies for preventing emphysema include large-scale public education campaigns and accessible cessation programs. The Brazilian Ministry of Health's "Eu Quero Parar de Fumar" (I Want to Quit Smoking) initiative uses mass media to raise awareness about the risks of smoking, including the development of emphysema and COPD [98]. The Sistema Único de Saúde (SUS) provides free treatment for tobacco dependence, including behavioral counseling, psychological support, and pharmacotherapy with nicotine replacement therapy, bupropion, and varenicline [99]. Studies have shown that this integrated approach significantly increases cessation success rates, with one program in Santa Catarina reporting that 70% of participants successfully quit smoking in 2024 [75]. The integration of these services into primary care is crucial for early intervention and long-term support [98].

Socioeconomic Disparities and Environmental Factors

Despite national successes, significant socioeconomic disparities persist. Smoking prevalence is higher among populations with lower income and education levels, who also face greater exposure to environmental and occupational risk factors such as air pollution and toxic dusts and fumes [102]. This creates a disproportionate burden of emphysema on vulnerable communities. Urban air pollution, particularly from traffic and industrial emissions, is a major environmental risk factor, with particulate matter (PM2.5) directly linked to a decline in lung function and worsening of COPD [103]. Occupational exposure in industries like mining, construction, and agriculture accounts for a significant portion of COPD cases, often occurring without adequate protective equipment or health monitoring [104]. Addressing these disparities requires multilevel policies that combine health, environmental, and labor regulations to protect at-risk populations.

Economic Impact and the Case for Prevention

The economic impact of emphysema and COPD on the SUS is substantial. In 2019 alone, direct hospital costs for COPD management reached approximately R$ 107.9 million [105]. The indirect costs are even more staggering, with over 196 million workdays lost between 2017 and 2022 due to premature mortality, disability, and early retirement, which cost the Brazilian social security system more than R$ 550 million over a decade [106]. These figures underscore that the disease represents a massive drain on national productivity and public resources. Investment in primary prevention, particularly tobacco control, offers a powerful return on investment. It is estimated that a 1% reduction in smoking prevalence could save the Brazilian health system R$ 24.8 billion annually [107]. Therefore, sustaining and strengthening public health policies for smoking cessation and environmental protection is not only a health imperative but also a critical economic strategy for reducing the long-term burden of emphysema.

Complications and Systemic Effects

Pulmonary emphysema, as a progressive form of chronic obstructive pulmonary disease (COPD), leads to a cascade of complications that extend beyond the lungs, affecting multiple organ systems and significantly impacting patient prognosis and quality of life. The irreversible destruction of alveolar walls and loss of pulmonary elasticity not only impair gas exchange but also initiate systemic processes that contribute to cardiovascular, metabolic, and musculoskeletal complications. These systemic effects are driven by chronic inflammation, hypoxemia, and the mechanical burden of hyperinflated lungs.

Pulmonary Hypertension and Cor Pulmonale

One of the most serious complications of advanced emphysema is the development of pulmonary hypertension, a condition characterized by elevated blood pressure in the pulmonary arteries. This occurs due to vascular remodeling and destruction of the pulmonary capillary bed as a consequence of alveolar damage [7]. Chronic hypoxemia triggers vasoconstriction of the pulmonary vasculature, while inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukin-8 (IL-8) promote endothelial dysfunction and vascular remodeling [13]. Over time, the increased resistance in the pulmonary circulation places excessive strain on the right ventricle of the heart, leading to right ventricular hypertrophy and eventually cor pulmonale, a form of right-sided heart failure [7]. Patients with cor pulmonale may present with peripheral edema, jugular venous distension, and hepatomegaly, and the condition is associated with increased mortality.

Systemic Inflammation and Cardiovascular Risk

Chronic inflammation in emphysema is not confined to the lungs; it spills over into the systemic circulation, contributing to a heightened risk of cardiovascular diseases. Inflammatory cytokines such as TNF-α, interleukin-6 (IL-6), and C-reactive protein (CRP) are elevated in patients with emphysema and are linked to endothelial dysfunction, atherosclerosis, and increased risk of myocardial infarction and stroke [111]. The persistent activation of immune cells like neutrophils and alveolar macrophages sustains this systemic inflammatory state, which interacts with traditional cardiovascular risk factors such as smoking and aging [112]. This systemic inflammation also contributes to the development of insulin resistance and metabolic syndrome, further compounding the cardiovascular burden.

Skeletal Muscle Dysfunction and Cachexia

Patients with severe emphysema often experience significant weight loss and muscle wasting, a condition known as pulmonary cachexia. This results from a combination of increased energy expenditure due to the work of breathing, systemic inflammation, and reduced physical activity. Elevated levels of pro-inflammatory cytokines, particularly TNF-α, promote muscle catabolism and inhibit protein synthesis [113]. Additionally, chronic hypoxemia and oxidative stress impair mitochondrial function in skeletal muscles, leading to early fatigue and reduced exercise tolerance. This muscle dysfunction creates a vicious cycle, as decreased physical activity further accelerates deconditioning and worsens dyspnea. The presence of cachexia is a strong predictor of poor outcomes and reduced survival in COPD patients.

Oxidative Stress and Cellular Senescence

The systemic effects of emphysema are also mediated by widespread oxidative stress, primarily driven by exposure to cigarette smoke and chronic inflammation. This leads to an overproduction of reactive oxygen species (ROS), which damage lipids, proteins, and DNA throughout the body [114]. Biomarkers such as malondialdehyde (MDA) and 8-isoprostane are elevated in patients and correlate with disease severity [115]. Oxidative stress also accelerates cellular senescence, a state of irreversible cell cycle arrest. Senescent cells accumulate in the lungs and other tissues, secreting pro-inflammatory factors through the senescence-associated secretory phenotype (SASP), which perpetuates inflammation and tissue damage [19]. This process contributes to the aging phenotype observed in emphysema patients and may underlie the increased risk of comorbidities such as cancer and frailty.

Respiratory Failure and Hypoxemia

As emphysema progresses, the loss of alveolar surface area and ventilation-perfusion mismatch lead to chronic hypoxemia and, in advanced stages, respiratory failure. The inability to effectively oxygenate the blood results in tissue hypoxia, which affects organ function and contributes to cognitive impairment, fatigue, and reduced quality of life. Chronic hypoxemia also stimulates erythropoiesis, leading to secondary polycythemia, which increases blood viscosity and further elevates the risk of thrombotic events [80]. In severe cases, hypercapnia (elevated carbon dioxide levels) may develop, indicating ventilatory failure and necessitating long-term oxygen therapy or non-invasive ventilation.

Impact on Mental Health and Quality of Life

The chronic nature of emphysema and its associated symptoms—particularly dyspnea and fatigue—have profound effects on mental health. Patients are at increased risk of developing anxiety and depression, which are often underdiagnosed and undertreated [118]. The progressive limitation in physical activity leads to social isolation and reduced independence, further diminishing quality of life. Comprehensive management must therefore include psychological support and interventions such as pulmonary rehabilitation, which has been shown to improve both physical and emotional well-being [76].

The systemic complications of emphysema underscore the importance of a holistic approach to management. Interventions such as smoking cessation, long-term oxygen therapy, pulmonary rehabilitation, and pharmacological treatments not only alleviate respiratory symptoms but also mitigate systemic effects and improve survival. Addressing these complications requires coordinated care involving pulmonologists, cardiologists, nutritionists, and mental health professionals to optimize outcomes for patients with this complex and multisystem disease.

Emerging Therapies and Research Directions

The landscape of pulmonary emphysema treatment is undergoing a transformative shift, moving beyond symptomatic management toward therapies that target the underlying molecular and cellular mechanisms of disease progression. While current standards of care, such as bronchodilators and oxygen therapy, remain essential, emerging research is focused on modulating key pathological pathways including chronic inflammation, oxidative stress, cellular senescence, and protease-antiprotease imbalance. These novel approaches aim to slow or halt the irreversible destruction of alveolar tissue, offering hope for disease modification rather than mere symptom control.

Targeting the Inflammasome and Chronic Inflammation

Chronic inflammation, driven by persistent activation of immune cells like neutrophils and alveolar macrophages, is a central feature of emphysema pathogenesis. A promising therapeutic target within this inflammatory cascade is the NLRP3 inflammasome, a multiprotein complex that, when activated, triggers the release of potent pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18. Inhibition of the NLRP3 inflammasome has been shown in preclinical models to reduce pulmonary inflammation and alveolar damage associated with emphysema [120]. By targeting this specific molecular complex, researchers aim to disrupt the self-perpetuating cycle of inflammation without causing broad immunosuppression, a significant limitation of traditional corticosteroids. This precision approach represents a shift toward more targeted anti-inflammatory strategies for chronic obstructive pulmonary disease (COPD).

Combating Oxidative Stress and Enhancing Antioxidant Defenses

Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) and the body's antioxidant defenses, plays a critical role in emphysema, particularly in smokers. ROS directly damage lung tissue and inactivate protective proteins like alpha-1 antitrypsin, exacerbating the protease-antiprotease imbalance. Emerging therapies are focused on restoring this balance. One key strategy involves activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a master regulator of antioxidant gene expression. Compounds such as sulforaphane, a natural isothiocyanate found in cruciferous vegetables, are being investigated as Nrf2 activators to boost the production of endogenous antioxidants like glutathione and superoxide dismutase (SOD) [121]. Additionally, direct-acting antioxidants, such as N-acetylcysteine, have shown some efficacy in reducing exacerbations, and next-generation mimetics of SOD and inhibitors of ROS-producing enzymes like NADPH oxidase are in development.

Addressing Cellular Senescence and Promoting Regeneration

Cellular senescence, a state of irreversible cell cycle arrest, is increasingly recognized as a key contributor to emphysema. Stressed and damaged lung cells, including epithelial and endothelial cells, become senescent and secrete a harmful mix of inflammatory cytokines, chemokines, and proteases known as the senescence-associated secretory phenotype (SASP). This creates a toxic microenvironment that drives further inflammation and tissue destruction while impairing repair mechanisms. A novel class of drugs called senolytics is being explored to selectively eliminate these senescent cells. By clearing the lung of these "zombie cells," senolytics aim to halt disease progression and potentially allow for tissue repair. Furthermore, research into regenerative medicine is investigating the use of mesenchymal stem cells (MSCs), which possess immunomodulatory and tissue-repair properties, as a potential therapy to promote alveolar regeneration and modulate the inflammatory environment [122].

Protease Inhibition and Epigenetic Modulation

Directly targeting the proteolytic enzymes responsible for alveolar destruction remains a viable strategy. While the focus has traditionally been on alpha-1 antitrypsin augmentation for genetic deficiency, new broad-spectrum or selective protease inhibitors are under investigation. For instance, nerandomilast, an inhibitor of dipeptidyl peptidase-1, has shown potential in slowing lung function decline in other fibrotic lung diseases and is being evaluated for its applicability to emphysema [123]. In parallel, the field of epigenetics is opening new avenues. Epigenetic modifications, such as DNA methylation and histone acetylation, can alter gene expression in response to environmental factors like cigarette smoke. Early research suggests that epigenetic drugs may be able to reverse smoke-induced changes in gene expression related to inflammation and senescence, offering a potential way to reset the pathological programming of lung cells [124].

Biomarkers and Personalized Medicine

The development of these targeted therapies is closely linked to the discovery of novel biomarkers for early diagnosis and disease monitoring. Researchers are identifying molecules in blood, urine, and sputum that reflect specific pathological processes, such as elastin degradation products (e.g., desmosine), inflammatory cytokines (e.g., IL-6, TNF-α), oxidative stress markers (e.g., malondialdehyde), and senescence markers (e.g., p16, p21). The integration of these biomarkers into clinical practice will be crucial for the success of emerging therapies, enabling a shift toward personalized medicine. By profiling a patient's specific disease mechanisms, clinicians could select the most appropriate targeted therapy, such as an inflammasome inhibitor for a patient with high IL-1β levels or a senolytic for one with evidence of accelerated cellular aging. This move from a one-size-fits-all approach to a precision medicine model holds the greatest promise for significantly altering the course of pulmonary emphysema in the future.

Socioeconomic Impact and Healthcare Burden

Pulmonary emphysema, as a major component of chronic obstructive pulmonary disease (COPD), imposes a substantial socioeconomic burden on healthcare systems and societies, particularly in countries with high smoking prevalence and aging populations. The disease leads to progressive disability, reduced productivity, and significant healthcare expenditures, with costs stemming from hospitalizations, long-term treatments, and premature disability. In Brazil, where the disease is closely linked to tobacco use, the impact on the Sistema Único de Saúde (SUS) and the social security system is particularly pronounced. Direct healthcare costs associated with COPD management, including hospital admissions for acute exacerbations and pharmacological treatments, reached approximately R$107.9 million in 2019 alone [105]. Medications account for about 71% of these direct costs, reflecting the reliance on long-term use of long-acting bronchodilators, inhaled corticosteroids, and combination therapies to manage symptoms and prevent deterioration [126].

Economic Costs and Productivity Loss

Beyond direct medical expenses, the indirect costs of emphysema are staggering. The disease contributes significantly to premature mortality and long-term disability, resulting in massive productivity losses. Between 2017 and 2022, COPD was responsible for over 196 million lost workdays in Brazil, primarily due to early deaths, sick leave, and early retirement [106]. Disability pensions due to COPD have cost the Brazilian social security system more than R$550 million over the past decade, with an average productivity loss of about 36 months per beneficiary [128]. These figures underscore the profound economic impact of a largely preventable disease. Research indicates that for every R$1 of profit generated by the tobacco industry in Brazil, the country spends approximately R$5 on healthcare costs and productivity losses, highlighting a severe economic imbalance [129]. The total annual cost of smoking-related diseases and disabilities in Brazil is estimated at around R$125 billion, with COPD and emphysema representing a significant portion of this burden [130].

Impact of Late Diagnosis on Healthcare Systems

Delayed diagnosis of pulmonary emphysema is a critical factor exacerbating its socioeconomic impact. Because symptoms like chronic cough and mild dyspnea are often dismissed as signs of aging or smoking, patients frequently present for medical care only in advanced stages of the disease, when lung function is severely compromised. This late diagnosis limits the effectiveness of interventions such as smoking cessation and pulmonary rehabilitation, which are most beneficial when initiated early [92]. As a result, patients are more prone to frequent and severe exacerbations, leading to higher rates of hospitalization and increased strain on healthcare resources. The high cost of managing advanced disease, including intensive care and long-term oxygen therapy, further inflates the financial burden on systems like the SUS. Early detection through routine spirometry screening in at-risk populations—such as smokers over 40 years of age or those exposed to occupational hazards—could significantly reduce these costs by enabling timely intervention and slowing disease progression [9].

Effectiveness of Prevention and Policy Interventions

Investing in primary prevention, particularly tobacco control, offers a powerful strategy to reduce the long-term socioeconomic burden of emphysema. Evidence shows that effective public health policies can yield substantial economic returns. For example, increasing tobacco taxes, a key element of the WHO’s MPOWER framework, has been shown to reduce smoking rates, especially among youth and low-income groups. A mere 1% reduction in smoking prevalence in Brazil could save an estimated R$24.8 billion annually in healthcare costs [107]. Additionally, implementing brief smoking cessation counseling in primary care settings could have saved the SUS up to R$1 billion in treatment costs [134]. Brazil’s success in reducing adult smoking rates from 15.7% to 9.1% between 2006 and 2023, through comprehensive tobacco control policies, demonstrates the feasibility of such interventions [93]. However, the recent reversal in this trend, with smoking rates rising to 11.6% in 2024, threatens to undermine these gains and increase future healthcare costs [97].

Health Inequities and Vulnerable Populations

The burden of emphysema is not distributed equally across society. Significant health inequities exist, with lower-income and less-educated populations facing higher risks due to greater exposure to tobacco, occupational hazards, and environmental pollution. Workers in industries such as mining, construction, and agriculture are often exposed to dusts, fumes, and gases that contribute to the development of COPD, yet they frequently lack adequate protective equipment or access to occupational health monitoring [104]. In urban areas, residents of low-income neighborhoods and favelas are disproportionately exposed to high levels of air pollution from traffic and waste burning, further increasing their respiratory risk [138]. These populations also face barriers to healthcare access, leading to delayed diagnosis and poorer outcomes. The intersection of socioeconomic disadvantage, environmental exposure, and limited healthcare access creates a cycle of disease and poverty that amplifies the overall burden of emphysema on the healthcare system [139].

Strategies for Reducing the Burden

To mitigate the socioeconomic impact of emphysema, a multifaceted approach is required. This includes strengthening tobacco control policies, expanding access to smoking cessation programs within the SUS, and implementing targeted screening for early detection. Programs that integrate pulmonary rehabilitation and patient education have been shown to reduce hospitalizations, improve quality of life, and decrease healthcare utilization [76]. The use of emerging technologies, such as telemonitoring and wearable devices, may also enhance disease management and reduce the need for in-person visits and hospital admissions, as seen in pilot programs in Portugal [141]. Ultimately, sustained investment in prevention, early diagnosis, and equitable access to care is essential to reduce the human and economic toll of pulmonary emphysema. By addressing the root causes—particularly tobacco use and environmental exposures—health systems can achieve long-term savings and improve population health outcomes.

References